PT - JOURNAL ARTICLE AU - ONDREJ FIALA AU - MILOS PESEK AU - JINDRICH FINEK AU - LUCIE BENESOVA AU - MAREK MINARIK AU - ZBYNEK BORTLICEK AU - ONDREJ TOPOLCAN TI - The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC DP - 2014 Sep 01 TA - Anticancer Research PG - 5193--5198 VI - 34 IP - 9 4099 - http://ar.iiarjournals.org/content/34/9/5193.short 4100 - http://ar.iiarjournals.org/content/34/9/5193.full SO - Anticancer Res2014 Sep 01; 34 AB - Background/Aim: Tumor biomarkers are used for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on the predictive role of neuron-specific enolase (NSE) and thimidine kinase (TK) in patients with advanced-stage NSCLC treated with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). Patients and Methods: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. Results: We observed significantly shorter progression-free (PFS) and overall survival (OS) in patients with high NSE levels (p=0.002; p=0.003) and also in those with high TK levels (p=0.026; p=0.020). The multivariate Cox proportional hazards model confirmed that high NSE is a strong independent predictive factor for short PFS (hazard ratio; HR=2.36; p=0.003). Conclusion: High pre-treatment serum levels of NSE is an independent biomarker predicting poor outcome of patients with NSCLC treated with EGFR-TKIs.